Search

Displaying results 5861 - 5870 of 7604 in total
  1. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

  2. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  3. Drug

    Cardarine

    go.drugbank.com/drugs/DB05416
    Investigational

    Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.

  4. Drug

    Siplizumab

    go.drugbank.com/drugs/DB06371
    Investigational

  5. Drug

    Recombinant Super-Compound Interferon

    go.drugbank.com/drugs/DB15752
    Investigational

    Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.

    Synonyms: rSIFN-co
  6. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  7. Drug

    Suxibuzone

    go.drugbank.com/drugs/DB13232
    Experimental

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  8. Drug

    Pirprofen

    go.drugbank.com/drugs/DB13722
    Experimental

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  9. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the

  10. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.